The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - UniQure’s (QURE) presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is only a week … Continue Reading
Read nowInsights - The long-awaited September meeting of the FOMC takes place this coming Thursday. Market participants are unusually attuned to this particular meeting due to the ongoing … Continue Reading
Read nowResearch - Last week was yet another exhausting, anemic few sessions in the markets. One day we're up, and the next we're down - with gaps nonetheless - but a trend is non-existent.
PremiumInsights - After repeat attempts to convince the U.S. FDA that the company should not be required to run another clinical trial, it appears AcelRx Pharmaceuticals (ACRX) may have finally … Continue Reading
Read nowInsights - After the last two weeks, everyone’s ready for a 3-day break. August closed out with the S&P 500 down 6%, and the NASDAQ Biotech Index … Continue Reading
Read nowInsights - Amicus Therapeutics (FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own. Amicus announced early Monday that it will buy … Continue Reading
Read nowInsights - That was the rumor on anyway, sending shares of Ariad Pharmaceuticals (ARIA) higher by 40% in the Friday trading session. Bloomberg reported at noon on … Continue Reading
Read now
